Abstracts tagged "giant cell arteritis"

Abstract Number: 2703 • ACR Convergence 2025
Longitudinal Changes on Cranial Magnetic Resonance Imaging in Relapsing Giant Cell Arteritis
Ruoheng Zeng¹, Ryan Rebello², Konstanze Guggenberger³, Joshua Baker⁴, Shubhasree Banerjee⁴, Robert Kurtz⁴, Naomi Amudala⁴, Peter Merkel⁴ and Rennie Rhee⁴, ¹University of Pennsylvania School of Medicine, Philadelphia, PA, ²St. Joseph’s Hospital at McMaster University, Hamilton, ON, Canada, ³University Hospital of Wuerzburg, Wuerzburg, Germany, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: There is a need for better tools to monitor disease activity in giant cell arteritis (GCA). Prior studies demonstrated that vascular enhancement on cranial…
Abstract Number: 1175 • ACR Convergence 2025
Secukinumab In Patients with Giant Cell Arteritis with Polymyalgia Rheumatica Symptoms: A Post Hoc Analysis of the Phase 2 TitAIN Study
Nils Venhoff¹, Wolfgang Schmidt², Raoul Bergner³, Juergen Rech⁴, Leonore Unger⁵, Stephanie Finzel⁶, Ioana Andreica⁷, David Kofler⁸, Stefan Weiner⁹, Prof. Dr. med. Peter Lamprecht¹⁰, Hendrik Schulze-Koops¹¹, Meryl Mendelson¹², Weibin Bao¹³, Monica Keyport¹⁴, Meron Maricos¹⁵, Valeria Jordan M.¹⁶ and Jens Thiel¹⁷, ¹University of Freiburg, Freiburg, Germany, ²Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch; Waldfriede Hospital, Rheumatology, Berlin, Germany, ³Department of Internal Medicine A, Nephrology and Rheumatology, Municipal Hospital Ludwigshafen, Ludwigshafen, Germany, ⁴Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁵Städtisches Klinikum Dresden, Dresden, Germany, ⁶Universitétsklinikum Freiburg, Freiburg im Breisgau, Germany, ⁷Rheumazentrum Ruhrgebiet Herne; Ruhr-Universität Bochum, Germany, Herne, Germany, ⁸University of Cologne, Cologne, Germany, ⁹Brüderkrankenhaus Trier, Trier, Germany, ¹⁰University of Lübeck, Lübeck, Germany, ¹¹LMU Hospital, Division for Rheumatology and Clinical Immunology, Munich, Bayern, Germany, ¹²Novartis Pharmaceuticals, Larchmont, NY, ¹³Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹⁴Novartis Pharmaceuticals, Stillwater, MN, ¹⁵Novartis, Nürnberg, Germany, ¹⁶Novartis Pharmaceuticals Corporation, Tenafly, NJ, ¹⁷University Hospital Freiburg, Medical University Graz, Freiburg, Germany
Background/Purpose: GCA and PMR are closely related, immune-mediated chronic inflammatory diseases often occurring concurrently in individuals over 50.1,2 While glucocorticoids (GC) are the mainstay of…
Abstract Number: 0759 • ACR Convergence 2025
Distinct differences between giant cell arteritis diagnosed by fluorodeoxyglucose (FDG) positron emission tomography (PET) versus temporal artery biopsy-a comparative cohort study
Sehreen Mumtaz¹, Lerone Clark², Archit Srivastava², Hannah Langenfeld³, Andrew C. Hanson³, Cynthia Crowson⁴, Andy Abril², Nouran Eshak⁵, Megan Sullivan⁶, Matthew Koster³ and Kenneth Warrington³, ¹Mayo Clinic Florida, Jacksonville, FL, ²Mayo Clinic, Florida, Jacksonville, FL, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Stewartvillle, MN, ⁵Mayo Clinic, Arizona, Scottsdale, AZ, ⁶Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Giant cell arteritis (GCA) is clinically heterogenous, and the presenting manifestations may influence diagnostic testing. The aim of this study was to evaluate the…
Abstract Number: 0742 • ACR Convergence 2025
Exploring Racial Variation in the Clinical Manifestations of Giant Cell Arteritis: A Retrospective Single-Center Study
Dana Nachawati¹, Chelsea Guan¹, Amir Daneshvar¹, Ansaam Daoud² and Omer Pamuk³, ¹University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ²Case Western Reserve University/University Hospitals, Cleveland, OH, ³University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Giant cell arteritis (GCA) is a large and medium vessel vasculitis affecting older adults of Northern European descent. While GCA is well characterized in…
Abstract Number: 2702 • ACR Convergence 2025
Diagnostic Performance of Vascular Ultrasound in Giant Cell Arteritis – A Single Center Experience
Ruoning Ni¹, Carol Langford², Minna Kohler³, amne Dargham¹, Irene Katzan¹, Chao Zhang⁴ and Rula Hajj-Ali¹, ¹Cleveland Clinic, Cleveland, ²Cleveland Clinic, Moreland Hills, OH, ³Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Cleveland Clinic, Cleveland Heights, OH
Background/Purpose: Diagnostic approaches to giant cell arteritis (GCA) differ between the United States (U.S.) and Europe, with Europe favoring rheumatologist-performed ultrasound and the U.S. relying…
Abstract Number: 1097 • ACR Convergence 2025
Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic review and meta-analysis highlighting differences with the idiopathic forms
Elvis Hysa¹, Andrea Casabella², Emanuele Gotelli³, Rosanna Campitiello⁴, Carlo Genova⁴, Enrica Teresa Tanda⁴, Carmen Pizzorni⁵, Alberto Sulli⁵, Vanessa Smith⁶, Marco Amedeo Cimmino⁷, Sabrina Paolino⁵ and Maurizio Cutolo⁴, ¹University of Genoa, Genoa, Italy, ²IRCCS Ospedale Policlinico San Martino, Genova, Italy, ³University of Genoa, Genoa, Liguria, Italy, ⁴University of Genova, Genova, Italy, ⁵University of Genoa, Genova, Italy, ⁶Ghent University Hospital, Gent, Belgium, ⁷Rheumatology Outpatient Clinic, Villa Ravenna, Chiavari, Italy, Genova, Italy
Background/Purpose: An altered immune tolerance disturbed by immune checkpoint inhibitors (ICIs) may contribute to new-onset polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in treated…
Abstract Number: 0757 • ACR Convergence 2025
The role of Methotrexate in the treatment of Giant Cell Arteritis: data from the ARTESER registry.
Pablo Muñoz-Martínez¹, Marta Domínguez-Álvaro², Lucia Otero³, Clara Moriano⁴, Julio Sánchez Martín⁵, Javier Narváez⁶, Eva Galíndez Agirregoikoa⁷, Javier Mendizábal⁸, lydia Abasolo Alcazar⁹, Javier Loricera¹⁰, Alejandro Muñoz¹¹, Santos Castañeda¹², rafeal Benito-Melero¹³, Carmen Larena¹⁴, Paula Estrada-Alarcón¹⁵, Carlos Galisteo¹⁶, Anne Riveros frutos¹⁷, Francisco Ortiz sanjuán¹⁸, Tarek Salman Montes¹⁹ and Ricardo Blanco²⁰, ¹Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Spanish Society of Rheumatology, Madrid, Spain, ⁴Hospital León, LEON, Castilla y Leon, Spain, ⁵Hospital Universitario ¹² de Octubre, Madrid, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ⁸Navarra Hospital, Pamplona, Spain, ⁹IdISSC. HCSC, Madrid, Madrid, Spain, ¹⁰Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ¹¹Hospital Universitario Virgen del Rocío, Sevilla, Andalucia, Spain, ¹²Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹³MD, barcelona, Spain, ¹⁴Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ¹⁵Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ¹⁶Hospital Parc Taulí, Sabadel, Sabadel, Spain, ¹⁷Hospital Germans Trias i Pujol, Barcelona, Spain, ¹⁸Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain, ¹⁹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ²⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most common large-vessel vasculitis, and its cornerstone treatment is the use of corticosteroids (CS). Various therapies have been…
Abstract Number: 0740 • ACR Convergence 2025
Intravenous versus subcutaneous administration of Tocilizumab in aortitis associated with giant cell arteritis: multicenter open-label study of 196 patients
Carmen Secada-Gómez¹, Javier Loricera², Adrian Martin-Gutierrez³, Santos Castañeda⁴ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain
Background/Purpose: Aortitis associated to Giant cell arteritis (GCA) (GCA-aortitis) is one of the most severe manifestation of GCA. Tocilizumab (TCZ) has demonstrated efficacy in large-vessel…
Abstract Number: 2584 • ACR Convergence 2025
Spatially Resolved Transcriptomics Reveal Macrophage Heterogeneity in Giant Cell Arteritis
Lea Dionet¹, Federica Pallotti², Margot Poux³, Quentin Delcros⁴, Nader Yatim⁵, Brian Soong⁶, Paul Breillat⁷, Kevin Chevalier⁸, claudie Cladière⁹, Patrick Bruneval¹⁰, Benoit Terris⁴, Alexis REGENT¹¹, Xavier Puéchal¹², Luc Mouthon¹³, Miriam Merad⁶, Olivia Lenoir¹⁴, Pierre-Louis Tharaux¹⁵, Maxime Samson¹⁶ and Benjamin Terrier¹⁷, ¹INSERM, Paris, France, ²Internal Medicine and Clinical Immunology, Rennes, France, ³Université de Paris, PARIS ⁰⁴EME, France, ⁴AP-HP, Paris, France, ⁵University of Paris-Cite, New York, NY, ⁶Mount Sinai School of Medicine, New York, ⁷INSERM, PARIS ¹⁷, Ile-de-France, France, ⁸Université Paris Cité, Montrouge, France, ⁹Marie et Louis Pasteur University, EFS, INSERM, UMR RIGHT, Besançon, France, Dijon, France, ¹⁰AP-HP, Paris, ¹¹Hopital Cochin, Paris, France, ¹²Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ¹³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ¹⁴Paris Cardiovascular Research Center, Université Paris Cité, INSERM U⁹⁷⁰, Paris, France, PARIS, Ile-de-France, France, ¹⁵Paris Cardiovascular Research Center, Université Paris Cité, INSERM U⁹⁷⁰, Paris, France, PARIS, France, ¹⁶CHU Dijon Bourgogne, Dijon, France, ¹⁷Cochin Hospital, Paris, France
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel vasculitis affecting individuals over 50 years of age. Current models implicate genetic susceptibility, immune senescence, activation of…
Abstract Number: 1075 • ACR Convergence 2025
Racial Differences in Management and Clinical Outcomes of Giant-Cell Arteritis: A Real-World Propensity-Matched Study
Michael Hamilton¹, Justin Riley Lam², Emmanuel Otabor³, Laith Alomari³, Maxim Barnett³, Fabian Rodriguez Quinonez⁴ and Irene Tan⁵, ¹Jefferson Einstein Hospital, Philadelphia, Philadelphia, PA, ²Jefferson Einstein Hospital, Philadelphia, PA, ³Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ⁴Einstein Medical Center Philadelphia, Philadelphia, PA, ⁵Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Giant-cell arteritis (GCA) is usually described in people of Northern-European ancestry, and little is known about outcomes in Black and Hispanic (B-His) patients. Using…
Abstract Number: 0756 • ACR Convergence 2025
Stroke Characteristics in Giant Cell Arteritis and Takayasu Arteritis: A Multicenter Cohort Study of 108 Patients
Omar Dhrif¹, Charlotte Caudron², Simon Parreau³, Eric Liozon³, Adrien Mirouse⁴, Jean-François Alexandra⁵, Laurent Sailler⁶, Mathieu Groh⁷, Hubert De Boysson⁸, Mikael Ebbo⁹, Cloé Comarmond¹⁰, Cécile Audrey Durel¹¹, Juliette Woessner¹², Pierre-André Jarrot¹³, Kévin Didier¹⁴, Goulabchand Radjiv¹⁵, Cacoub Patrice¹⁶, Bernard Bonnotte¹⁷, David Saadoun¹⁶ and Maxime Samson¹, ¹CHU Dijon Bourgogne, Dijon, France, ²CENTRE HOSPITALIER UNIVERSITAIRE DE DIJON, Paris, France, ³CHU de Limoges, Limoges, France, ⁴Médecine Interne et Immunologie Clinique, Groupe Hospitalier Pitié-Salpêtrière, APHP, Paris, Paris, France, ⁵Internal Medicine, Hôpital Bichat, APHP, Paris, France, ⁶CHU Toulouse, Toulouse, France, ⁷Hôpital Foch, Suresnes, France, ⁸Internal Medicine, CHU Caean, Caen, France, ⁹Internal Medicine, Marseille-APHM, hôpital La Timone, Marseille, France, ¹⁰Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U⁹⁴², Paris, France, ¹¹Médecine Interne, Hôpital Saint Joseph Saint Luc, Lyon, Lyon, France, ¹²Médecine Interne, CH d’Avignon, Avignon, Avignon, France, ¹³Médecine Interne, Hôpital de la Conception, APHM, Marseille, Marseille, France, ¹⁴Médecine Interne, CHU Reims, Reims, Reims, France, ¹⁵Médecine Interne, CHU Nîmes, Nîmes, Nîmes, France, ¹⁶Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoimmunes et systémiques rares, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire (CEREMAIA), INSERM, UMR S⁹⁵⁹, Immunology-Immunopathology-Immunotherapy (I³), Paris, France, Paris, France, ¹⁷Internal medicine and clinical immunology, Université Bourgogne Europe , CHU Dijon Bourgogne, Dijon, France
Background/Purpose: In giant cell arteritis (GCA) and Takayasu arteritis (TA), strokes occur in approximately 7.4% and 15.8% of cases, respectively. Although these two large-vessel vasculitides…
Abstract Number: 0741 • ACR Convergence 2025
Characteristics of African American vs. Non-African American Patients with Giant Cell Arteritis: A Retrospective Cohort Study
Dana Nachawati¹, Milad Heydari-Kamjani², Keri Ann Pfeil¹, Elleson Harper¹, Meghan Gump¹, Lindsay Frumker¹, Ansaam Daoud³ and Omer Pamuk², ¹University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ²University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ³Case Western Reserve University/University Hospitals, Cleveland, OH
Background/Purpose: GCA is a vasculitis of large and medium-sized arteries that has been well-studied in populations of European descent; however, data on African American (AA)…
Abstract Number: 2532 • ACR Convergence 2025
Temporal arteritis revealing eosinophilic diseases: A multicenter retrospective study, literature review, and combined cluster analysis
Julie Merindol¹, Benjamin Torreau², Matthieu Groh³, Amy Klion⁴, Paolo Delvino⁵, Olivier Espitia⁶, Jean-Benoit Arlet⁷, Sarah Lechtman⁸, Jean-sébastien Allain⁹, Federica Bello¹⁰, Anaelle Boucaud¹¹, Florian Catros¹², Julien Campagne¹³, Anne Coutard¹⁴, Cecile-Audrey DUREL¹⁵, Mikael Ebbo¹⁶, Georgina Espigol-Frigole¹⁷, Giacomo Emmi¹⁸, Yanis Kouchit¹⁹, Guillaume Lefevre²⁰, François Lifermann²¹, PAUL LEGENDRE²², Eric Liozon²³, Francois Maurier²⁴, Sara Melboucy Belhkir²⁵, Sébastien Miranda²⁶, Simon Parreau²³, Paola Parronchi²⁷, Jacques Pouchot²⁸, Vincent Pestre²⁹, Sophie Rosenstingl³⁰, Jan Willem Cohen Tervaert³¹, Odile Souchaud Debouverie³², Xavier Puéchal³³ and Benjamin Terrier³⁴, ¹CHU de Nice, Nice, France, ²Internal Medicine and Immunology, CHU Tours, Tours, France, ³Hôpital Foch, paris, France, ⁴NIAID/NIH, Bethesda, MD, ⁵University of Milano-Bicocca, Monza, Monza and Brianza, Italy, ⁶CHU de Nantes, Nantes, France, ⁷APHP, Paris, ⁸CHU de Nice, Nixe, France, ⁹Scorff-Lorient Hospital, Lorient, France, ¹⁰Université de Florence, Florence, Italy, ¹¹CHU de Tours, Tours, France, ¹²CHI VAL, Ariège, France, ¹³Hopital Robert Schuman, Metz, France, ¹⁴Groupe Hospitalier de Bretagne Sud, Lorient, France, ¹⁵CHU de Lyon, Lyon, France, ¹⁶Internal Medicine, Marseille-APHM, hôpital La Timone, Marseille, France, ¹⁷Hospital Clínic de Barcelona, Barcelona, Spain, ¹⁸Department of Medical, Surgery and Health Sciences, University of Trieste, Italy and Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Italy, Trieste, Italy, ¹⁹CH de Cannes, Cannes, France, ²⁰CHU de Lille, Lille, France, ²¹Internal Medicine, CH de Dax, Dax, France, ²²CH LE MANS, Le Mans, France, ²³CHU de Limoges, Limoges, France, ²⁴HOPITAUX PRIVES DE METZ, Vaux / Frankreich, France, ²⁵CH de Saint Quentin, Saint Quentin, France, ²⁶Internal Medicine, CHU Rouen, Rouen, France, ²⁷CHU de Florence, Florence, Italy, ²⁸AP-HP, Rueil Malmaison, France, ²⁹CH d'Avignon, Avignon, France, ³⁰CH de Compiegne, Compiegne, France, ³¹University of Alberta, Edmonton, AB, Canada, ³²CHU de Poitiers, Poitiers, France, ³³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ³⁴Cochin Hospital, Paris, France
Background/Purpose: Temporal arteritis (TA) classically presents as a large-vessel vasculitis in older adults with cranial ischemic symptoms. However, in younger patients or in the presence…
Abstract Number: 1047 • ACR Convergence 2025
Primary Care Perspectives on Giant Cell Arteritis: Diagnostic Considerations, Referral Challenges, and Opportunities for Fast-Track Pathways in the U.S.
Ellen Ann Sockman¹, Jon Golenbiewski¹ and Rachel Wolfe², ¹Wake Forest University School of Medicine, Winston-Salem, NC, ²Wake Forest University School of Medicine, Winston-Salem
Background/Purpose: Giant Cell Arteritis (GCA) is a medical emergency that can lead to irreversible vision loss without prompt recognition and treatment. Primary care providers (PCPs)…
Abstract Number: 0755 • ACR Convergence 2025
Sex Differences in Subtypes of Vascular Involvement and Clinical Manifestations in Giant Cell Arteritis
Natalia Lopez Juanes, Carlota Ureta, Irene Monjo Henry, Maria-Eugenia Miranda-Carus, Chamaida Plasencia-Rodríguez and Eugenio de Miguel, Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Recognizing gender-specific differences in diseases is critical to improve diagnostic and therapeutic strategies. Giant cell arteritis (GCA) has been traditionally considered a predominantly female…

1
2
3
…
36
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].